Lutein & Zeaxanthin
Tagetes erecta / Zea mays (dietary sources)
Dietary carotenoids that concentrate in the retina's macular pigment and modestly slow progression to advanced macular degeneration.
Moderate evidence
⏳Longevity
Evidence tier
Moderate
Research weight
Citations
19 verified / 19
Classification
Longevity
❝
What the evidence says. Several controlled trials; effects real but modest or context-dependent.
What is Lutein & Zeaxanthin?
Lutein & Zeaxanthin (Tagetes erecta / Zea mays (dietary sources)) is a longevity supplement used for modestly reduces the risk of progression to late (advanced) age-related macular degeneration in people with intermediate amd, per the large areds2 trial and its 10-year follow-up.. NutriDex grades the human evidence as Moderate. Lutein and zeaxanthin are dietary xanthophyll carotenoids (from leafy greens, corn, egg yolk, and marigold extracts) that selectively accumulate in the macula of the retina, forming the macular pigment that filters high-energy blue light and quenches oxidative damage. The strongest evidence comes from the AREDS2 randomized trial and its 10-year follow-up, which showed that adding 10 mg lutein plus 2 mg zeaxanthin to an antioxidant-mineral formula modestly slowed progression to late age-related macular degeneration (hazard ratio about 0.91) in people already at intermediate risk, and was superior to and safer than beta-carotene. Supplementation at roughly 10 mg/day or more dependably increases macular pigment optical density, a plausible biological mechanism, though larger doses produce larger effects. Claims for improved everyday vision, glare recovery, and cognitive performance are biologically plausible but supported only by small, mixed trials. There is no good evidence that these carotenoids prevent macular degeneration in healthy eyes or restore lost vision, so the overall benefit is real but modest and confined mainly to those with established intermediate AMD.
Purported Benefits
✓Modestly reduces the risk of progression to late (advanced) age-related macular degeneration in people with intermediate AMD, per the large AREDS2 trial and its 10-year follow-up.
✓Reliably raises macular pigment optical density (MPOD), the retinal pigment layer that filters blue light and reduces oxidative stress, at doses of roughly 10 mg/day or higher.
✓Serve as the safer replacement for beta-carotene in the AREDS2 eye-vitamin formula, avoiding the elevated lung-cancer risk seen with beta-carotene in smokers.
✓Possible but unproven benefits for visual function (glare recovery, contrast sensitivity) and cognition in older adults; trials are small and inconsistent, so these claims remain preliminary.
✓No solid evidence that supplements prevent AMD in healthy eyes or reverse existing vision loss.
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Progression to late AMD (intermediate-AMD patients)AREDS2 primary endpoint was null; benefit (HR~0.91) emerged in follow-up and as beta-carotene substitute. Modest, confined to at-risk eyes. | Moderate | ↑ benefit · small | 3 |
| Macular pigment optical density (MPOD)Many RCT meta-analyses reliably show dose-dependent MPOD increase at >=10 mg/day; a surrogate, not a clinical outcome. | Strong | ↑ benefit · moderate | 4 |
| Safer beta-carotene substitute (lung-cancer avoidance)AREDS2 showed lutein/zeaxanthin matched/exceeded beta-carotene without its near-doubled lung-cancer risk in smokers. | Strong | ↑ benefit · moderate | 2 |
| Cognition / memory in older adultsTwo small RCTs show gains in attention/visual memory; small, short, inconsistent across domains. | Preliminary | ↑ benefit · small | 2 |
| Visual function (contrast sensitivity, glare recovery)Network meta-analyses show shortened photostress recovery and contrast gains, but visual-acuity benefit only in diseased eyes; low certainty. | Preliminary | ↔ mixed · small | 3 |
Dosing & Compounds
Typical Dose
10 mg lutein + 2 mg zeaxanthin daily (the AREDS2 dose); MPOD studies suggest ≥10 mg/day total is needed for measurable effect. Best absorbed with a fat-containing meal.
Active Compounds
Safety & Cautions
Generally recognized as safe at typical supplemental doses (up to ~20 mg/day lutein); the AREDS2 dose of 10 mg lutein + 2 mg zeaxanthin showed no serious adverse effects over 10 years. Very high or prolonged intake can cause carotenodermia (a harmless yellow-orange skin tint) that reverses on stopping. Unlike beta-carotene, lutein/zeaxanthin did NOT raise lung-cancer risk in AREDS2, making them the preferred carotenoids for current and former smokers. Safety in pregnancy and breastfeeding at high supplemental doses is not well established, so dietary intake is preferred and supplements should be discussed with a clinician. No clinically important drug interactions are well documented, though absorption depends on dietary fat and may be reduced by fat-blocking agents (e.g., orlistat) or bile-acid sequestrants. People with AMD should use these supplements as part of a clinician-directed AREDS2 regimen rather than self-treating, and no one should expect them to reverse existing vision loss. Educational only — always check with your doctor or pharmacist before combining Lutein & Zeaxanthin with any medicine.
Key Studies ★ 19 studies
Systematic review
Hu (Advances in Nutrition) 2024
✓ PubMed
Systematic review and network meta-analysis of 38 RCTs across 8 antioxidant groups. All supplement groups significantly increased macular pigment optical density and contrast sensitivity at low spatial frequency. Lutein + zeaxanthin + fatty acid ranked best for MPOD (SUCRA 99.3%); lutein + zeaxanthin significantly shortened photostress recovery time (HR -5.75; 95% CI -8.80 to -1.70). Evidence quality rated low.
Meta-analysis
Hu (Nutrition Reviews) 2023
✓ PubMed
Systematic review, meta-analysis and meta-regression of up to 43 RCTs. Xanthophyll (lutein/zeaxanthin) intake increased MPOD by heterochromatic flicker photometry (WMD 0.05; 95% CI 0.03-0.07) and autofluorescence (WMD 0.08; 0.05-0.11), and shortened photostress recovery time (WMD -2.35 s). Visual acuity (logMAR) improved only in patients with eye disease (WMD -0.04; -0.07 to -0.01). MPOD gain correlated with rise in serum lutein.
Agency / regulator
NEI / NIH 2022
✓ Source
National Eye Institute statement confirming the AREDS2 10-year results: replacing beta-carotene with lutein/zeaxanthin reduced AMD progression risk by about 26% in those receiving it and avoided the increased lung-cancer risk seen with beta-carotene.
Systematic review and meta-analysis
46 studies, 3,189 participants
✓ Full text
Lutein/zeaxanthin supplementation increased macular pigment optical density in a dose-dependent way (mean difference +0.04 units at 5-<20 mg/day, +0.11 units at >=20 mg/day), with no significant effect below 5 mg/day.
Systematic review and meta-analysis
10 RCTs, 1,035 myopic participants
✓ Full text
In people with myopia, lutein and zeaxanthin supplementation significantly raised macular pigment optical density versus control (standardized mean difference 0.50, P=0.010).
Systematic review and network meta-analysis
Network meta-analysis of RCTs
✓ Source
Antioxidant supplements containing lutein significantly increased macular pigment optical density and low-frequency contrast sensitivity, but only lutein combined with antioxidants and fatty acids improved visual acuity.
Meta-analysis
Meta-analysis of 8 studies (1 cohort + 7 cross-sectional)
✓ PubMed
Higher blood concentrations of lutein and zeaxanthin were inversely associated with nuclear cataract risk (lutein pooled RR 0.73, 95% CI 0.59-0.87; zeaxanthin RR 0.63, 95% CI 0.49-0.77), with no significant association for cortical or subcapsular cataract.
RCT
Keenan/Chew 2024 (AREDS/AREDS2)
✓ Full text
Post hoc analysis of AREDS2 eyes with non-central geographic atrophy showed lutein/zeaxanthin vs none slowed proximity-based GA progression toward the fovea (80.1 vs 114.4 microm/year), an approximately 55% slower rate of foveal encroachment over ~3 years.
guideline
NIH NCCIH evidence digest for clinicians
✓ Source
This NIH NCCIH digest concludes that replacing beta-carotene with a 5-to-1 lutein/zeaxanthin mixture may further reduce risk of late AMD, and that in participants with the lowest dietary intake lutein/zeaxanthin was linked to a 32% reduction in progression to cataract surgery.
RCT
AREDS2 Research Group (Chew/Clemons) 2013
✓ PubMed
Landmark multicenter double-masked phase 3 RCT (n=4203, median 5-yr follow-up). Adding lutein 10 mg + zeaxanthin 2 mg to the AREDS formulation did NOT significantly reduce progression to advanced AMD in primary analysis (HR 0.90; 98.7% CI 0.76-1.07; P=.12; 5-yr progression 29% vs 31% placebo). However, lutein/zeaxanthin was identified as an appropriate substitute for beta carotene, which raised lung-cancer risk in former smokers.
Long-term follow-up of randomized trial (AREDS2 Report 28)
3,882 participants (6,351 eyes), 10-year follow-up
✓ Source
Adding lutein/zeaxanthin to the AREDS formula reduced progression to late AMD with a hazard ratio of 0.91 (95% CI 0.84-0.99), and was more effective than beta-carotene (HR 0.85 head-to-head).
Randomized double-masked placebo-controlled trial
51 older adults (mean age 73.7)
✓ PubMed
One year of 12 mg/day lutein+zeaxanthin produced statistically significant improvements in complex attention and cognitive flexibility versus placebo in healthy community-dwelling older adults.
Randomized double-blind placebo-controlled trial
70 adults aged 18-65 using screens >6 h/day, 6 months
✓ PubMed
Supplementation with 10 mg lutein plus 2 mg zeaxanthin-isomers significantly improved objective ocular measures versus placebo (Schirmer tear test, photo-stress recovery time, and tear film break-up time), though self-reported eye strain and sleep measures did not differ between groups.
rct
90 adults aged 40-75 with self-reported mild cognitive complaints, 6 months
✓ PubMed
Daily 10 mg lutein + 2 mg zeaxanthin produced significantly greater improvements than placebo in visual episodic memory (p=0.005) and visual learning (p=0.001), with no significant effect on other cognitive tests.
rct
65 healthy volunteers, double-blind placebo-controlled crossover, 12 weeks/arm
✓ Full text
Oral lutein supplementation significantly attenuated UVA/B- and UVA1-induced upregulation of inflammatory and photodamage gene markers in human skin, providing molecular evidence of photoprotection.
systematic_review
7 trials; lutein/zeaxanthin vs control mainly from AREDS2 (4,176 participants, 6,891 eyes)
✓ Full text
This 2023 Cochrane review found lutein/zeaxanthin alone had only similar-or-slightly-reduced risk of progression to late AMD versus control (RR 0.94, 95% CI 0.87-1.01; low-certainty), though as a beta-carotene replacement within the AREDS formula the hazard ratio was 0.82 (95% CI 0.69-0.96).
Cohort
AREDS2 Report 28 (Chew) 2022
✓ PubMed
10-year epidemiologic follow-up of the AREDS2 cohort (n=3882). Lutein/zeaxanthin vs no lutein/zeaxanthin reduced progression to late AMD (HR 0.91; 95% CI 0.84-0.99; P=.02); effect was stronger when restricted to the beta-carotene arm (HR 0.80; 0.68-0.92) and in direct comparison vs beta carotene (HR 0.85; 0.73-0.98). Beta carotene nearly doubled lung-cancer odds (OR 1.82) whereas lutein/zeaxanthin did not (OR 1.15).
Prospective cohort study
102,046 participants (63,443 women, 38,603 men), ~24-26 years follow-up
✓ PubMed
In the Nurses' Health Study and Health Professionals Follow-up Study, the highest versus lowest intake of bioavailable dietary lutein/zeaxanthin was associated with about a 40% lower risk of advanced (mostly neovascular) age-related macular degeneration (pooled RR 0.59; 95% CI 0.48-0.73; P-trend <0.001).
Prospective cohort study
22,472 US adults (NHANES), median 16.7-year follow-up, 7,901 deaths
✓ Full text
In a prospective NHANES cohort, the highest versus lowest quartile of serum lutein/zeaxanthin was associated with about 28% lower all-cause mortality (HR 0.72; 95% CI 0.67-0.77) in fully adjusted models.